Invention Grant
- Patent Title: Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigens
-
Application No.: US12232250Application Date: 2008-09-12
-
Publication No.: US09410139B2Publication Date: 2016-08-09
- Inventor: Gilles Dadaglio , Claude Leclerc , Daniel Ladant , Benoît Van Den Eynde , Sandra Morel , Cécile Bauche
- Applicant: Gilles Dadaglio , Claude Leclerc , Daniel Ladant , Benoît Van Den Eynde , Sandra Morel , Cécile Bauche
- Applicant Address: FR Paris FR Paris US NY New York FR Paris
- Assignee: INSTITUT PASTEUR,INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM),LUDWIG INSTITUT FOR CANCER RESEARCH,CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
- Current Assignee: INSTITUT PASTEUR,INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM),LUDWIG INSTITUT FOR CANCER RESEARCH,CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
- Current Assignee Address: FR Paris FR Paris US NY New York FR Paris
- Agency: Law Office of Salvatore Arrigo and Scott Lee, LLP
- Main IPC: C12N9/88
- IPC: C12N9/88 ; A61K38/16 ; A61K39/00 ; A61K39/39 ; A61K47/48
Abstract:
An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.
Public/Granted literature
- US20090117143A1 Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigens Public/Granted day:2009-05-07
Information query
